Journal publications

Export 76 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
2015
Mourad R, Chevennet F, Dunn DT, Fearnhill E, Delpech V, Asboe D, Gascuel O, Hue S.  2015.  A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK. AIDS. 29:1917-25.
2014
Hodcroft E, Hadfield J, Fearnhill E, Phillips AN, Dunn DT, O’Shea S, Pillay D, Leigh Brown A.  2014.  The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog. 10:e1004112.
Bulteel N, Bansi-Matharu L., Churchill D, Dunn DT, Bibby D., Hill T, Sabin CA, Nelson M.  2014.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.
UK HIV Drug Resistance Database.  2014.  The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 28:773-80.
Takebe Y., Naito Y., Raghwani J., Fearnhill E, Sano T., Kusagawa S., Mbisa JL, Zhang H, Matano T., Leigh Brown A et al..  2014.  Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan. J Virol. 88:9864-76.
Foster GM, Ambrose JC, Hue S, Delpech V, Fearnhill E, Abecasis AB, Leigh Brown A, Geretti AM.  2014.  Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D. PLoS One. 9:e83337.
Hue S, Brown A, Ragonnet-Cronin M, Lycett S, Dunn DT, Fearnhill E, Dolling D, Pozniak A, Pillay D, Delpech V et al..  2014.  Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions. AIDS. 28:1967-75.
2013
Ragonnet-Cronin M, Hodcroft E, Hue S, Fearnhill E, Delpech V, Leigh Brown A, Lycett S.  2013.  Automated analysis of phylogenetic clusters. BMC Bioinformatics. 14:317.
De Luca A., Dunn DT, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
Santoro MM, Sabin CA, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.
Dolling D, Dunn DT, Geretti AM, Sabin CA.  2013.  HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Clin Infect Dis. 56:162-3.
Mackie N, Dunn DT, Dolling D, Garvey L, Harrison LJ, Fearnhill E, Tilston P, Sabin CA, Geretti AM.  2013.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.
Dolling D, Dunn DT, Sutherland K.A, Pillay D, Mbisa JL, Parry C.M, Post FA, Sabin CA, Cane P A.  2013.  Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.
Castro H, Pillay D, Cane P A, Asboe D, Cambiano V, Phillips AN, Dunn DT.  2013.  Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.
Waters L., Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn DT, Phillips AN.  2013.  Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.
Koning FA, Castro H, Dunn DT, Tilston P, Cane P A, Mbisa JL.  2013.  Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 68:1220-36.
2012
Castro H, Pillay D, Sabin CA, Dunn DT.  2012.  Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol. 12:30.
Dolling D, Phillips AN, Delpech V, Pillay D, Cane P A, Crook A.M, Shepherd J., Fearnhill E, Hill T, Dunn DT.  2012.  Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13:309-14.
Barber TJ, Harrison LJ, Asboe D, Williams I, Kirk S., Gilson R, Bansi L, Pillay D, Dunn DT.  2012.  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.
Donegan K.L, Walker A.S, Dunn DT, Judd A, Pillay D, Menson E, Lyall H., Tudor-Williams G, Gibb DM.  2012.  The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther. 17:599-603.